Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2012-07-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Assess for hemodynamic differences at rest and with exercise between three clinically available tissue aortic valves.
2. Assess for differences in left ventricular (LV) reverse remodeling (recovery of LV hypertrophy, and changes in LV systolic and diastolic function) after aortic valve replacement for severe aortic stenosis (AS) between three clinically available aortic valve bioprosthesis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aortic Valve Replacement With Trifecta(TM)
NCT00475709
Aortic Valve Replacement With Trifecta(TM)
NCT00475267
In-vitro Benchmarking of Currently Available Heart Valve Prostheses for Surgical and Percutaneous Treatment of Aortic Stenosis With Small Annulus, Followed by In-vivo Validation
NCT06859255
Changes of Ascending Aortic Diameter in Patients Undergoing Transcatheter Aortic Valve Replacement
NCT05739253
A Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: The CHOICE Trial
NCT01645202
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Freestyle
Aortic valve replacement will be performed with a Freestyle stentless aortic bioprosthesis (Medtronic Cardiovascular; Minneapolis, MN).
Aortic valve replacement
Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
Magna Ease
Aortic valve replacement will be performed with a Magna Ease aortic bioprosthesis (Edwards Lifesciences; Irvine, CA).
Aortic valve replacement
Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
Trifecta
Aortic valve replacement will be performed with a Trifecta aortic bioprosthesis (St. Jude Medical; St. Paul, MN).
Aortic valve replacement
Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aortic valve replacement
Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Severe aortic stenosis (AS) based on overall clinical impression, with or without aortic valve mean gradient ≥ 40 mm Hg, EOA \< 1.0 cm2, or EOA index \< 0.6 cm2/m2.
* Scheduled for clinically indicated elective aortic valve replacement for a primary diagnosis of severe AS.
* Less than moderate aortic regurgitation on preoperative testing.
* Isolated aortic valve replacement; or aortic valve replacement with concomitant coronary artery bypass grafting, ascending aorta repair, or mitral and/or tricuspid annuloplasty for functional mitral regurgitation / tricuspid regurgitation.
* Left ventricular ejection fraction ≥ 40% on preoperative testing.
* Physically able and willing to pedal a recumbent bicycle.
* Patient and surgeon agree that the patient will undergo valve replacement with a bioprosthesis.
* Patient and surgeon agree that the use of one specific bioprosthesis manufacturer / model is not indicated based on clinical criteria.
* Willing to undergo randomization to have implanted one of three bioprosthesis at the time of aortic valve replacement.
* Willing and able to undergo preoperative echocardiography/Doppler for purposes of the research study.
* Willing and able to undergo post-operative exercise stress echocardiography/Doppler 5 to 7 months after valve replacement for purposes of the research protocol.
Exclusion Criteria
* AS felt by overall clinical impression to be less than severe.
* Aortic valve replacement is urgent or emergent.
* Moderate of more aortic regurgitation on preoperative testing.
* Concomitant mitral or tricuspid valve replacement.
* Left ventricular ejection fraction \< 40% on preoperative testing.
* Physically unable or unwilling to pedal a recumbent bicycle.
* Planned aortic valve replacement with a mechanical prosthesis.
* Operating surgeon believes that any one of the three protocol bioprosthetic devices is contraindicated based on clinical criteria.
* Not willing to undergo randomization to have implanted one of three bioprosthesis.
* Unwilling or unable to undergo preoperative echocardiography/Doppler for purposes of the research protocol.
* Unwilling or unable to undergo post-operative exercise stress echocardiography/Doppler 5 to 7 months after valve replacement for purposes of the research protocol.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Michigan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Bach, MD
Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Bach, MD
Role: PRINCIPAL_INVESTIGATOR
University of Michigan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Michigan Health Systems
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bach DS, Patel HJ, Kolias TJ, Deeb GM. Randomized comparison of exercise haemodynamics of Freestyle, Magna Ease and Trifecta bioprostheses after aortic valve replacement for severe aortic stenosis. Eur J Cardiothorac Surg. 2016 Aug;50(2):361-7. doi: 10.1093/ejcts/ezv493. Epub 2016 Jan 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N015029-00
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.